AB0879 Interim analysis of baseline characteristics and 12-week outcomes for a subset of patients with moderate-to-severe plaque psoriasis and psoriatic arthritis from the Psoriasis Study of Health Outcomes

Background Approximately 30% of patients (pts) with plaque psoriasis (PsO) develop psoriatic arthritis (PsA) 1 , which is associated high Psoriasis Area and Severity Index (PASI) nail involvement. The Study Health Outcomes (PSoHO) a 3-year (yr), international, prospective, observational cohort study comparing the effectiveness anti-IL-17A biologics to all other approved in pts moderate-to-severe PsO. Objectives This interim subset analysis describes baseline characteristics Week 12 (W12) PsO PsA PSoHO. Methods Adults for ≥6 months who initiated/switched biologic treatment during routine medical care were enrolled. diagnosis was recorded by dermatologists based on history and/or information provided patient. W12 assessed proportion achieving almost clear or skin defined ≥90% improvement PASI, affected Body Surface (BSA), Dermatology Life Quality (DLQI), Patient Global Assessment Disease (PatGA). Musculoskeletal endpoints not collected. Data analysed descriptively, using mean (standard deviation [SD]) median ([Q1/Q3]) continuous variables n, % 95% confidence limits categorical variables. Results Overall, 1981 enrolled this study, whom 461 (23.3%) had received either (n=227; 49.2%) (n=234; 50.8%). age 48.7 yrs disease duration 18.9 5.6 (Table 1). Table 1. Baseline PsA. Mean (SD) reported available data that measure, unless stated otherwise. Overall (n=461 ) Anti-IL-17A (n=227 Other Biologics (n=234 Age, (12.9) 50.9 46.6 (12.6) Male, n (%) 232 (50.3) 112 (49.3) 120 (51.3) BMI (kg/m 2 29.7 (6.2) 29.8 (5.9) 29.6 (6.4) Smoking status – Current, 100 (25.4) 41 (21.1) 59 (29.5) (PsA), yrs, (Q1/Q3) 5.6(2.2/13.1) 5.6(2.0 / 13.8) 5.5(2.3 12.8) (PsO), 18.9(9.7 28.6) 18.9(9.2 30.3) 18.7(10.1 27.3) Any previous therapy, 249 (54.0) 123 (54.2) 126 (53.8) PASI 14.3 (9.3) 13.6 (8.1) 15.0 (10.3) BSA, 21.7 (19.4) 19.8 (17.3) 23.5 mNAPSI 16.6 (22.8) 16.5 (25.5) 16.7 (20.1) Presence PsO, 217 (47.2) 103 (45.4) 114 (48.9) PatGA 3.5 (1.2) (1.3) 3.6 DLQI (7.9) 13.4 (7.8) 13.7 (8.0) HADS Depression score >10, 73 (19.3) 38 (20.5) 35 (18.1) Anxiety 124 (32.8) 62 (33.5) (32.1) = Mass Index; BSA Area; Hospital Scale; >10 indicates significant symptoms depression/anxiety; Modified Nail Severity; Q1/Q3 Quartile 1/3. At W12, 62.4% 42.6% anti-IL-17A-treated achieved PASI90 PASI100, respectively, compared 34.2% 16.8% cohort, respectively (Figure <3% reached 70.9% 49.5% while 71.2% 44.8%, 0/1. Among ≥2, 38.0% 27.1% cohorts, Figure Percentage receiving PASI75/90/100, absolute ≤1, <3%, 0/1 (baseline ≥2) at 12. Bars represent upper limits. Conclusion blocking IL-17A manifestations quality-of-life improvements real-world consistent observations from clinical trials. References [1]Zabotti A, et al. RMD Open 2019;5: e001067 Disclosure Interests Lars Erik Kristensen Speakers bureau: Pfizer, AbbVie, Amgen, UCB, Gilead, Biogen, BMS, MSD, Novartis, Eli Lilly, Janssen pharmaceuticals., Consultant of: Grant/research support from: IIT research grants Frank Behrens Roche, Chugai, Celgene, Biotest, Janssen, Genzyme, Boehringer Sandoz, GSK Luis Puig Abbvie, Almirall, Baxalta, Ingelheim, Bristol Myers Squibb, Fresenius-Kabi, JS BIOCAD, Leo-Pharma, Mylan, Regeneron, Samsung-Bioepis, Sanofi, Adam Reich Galderma, Thorsten Holzkaemper Shareholder Lilly Company, Employee Alan Brnabic Khai Ng Soyi Liu Leage Christopher Schuster Andreas Pinter Almirall-Hermal, Biogen Idec, Biontec, Boehringer-Ingelheim, GSK, Hexal, LEO-Pharma, MC2, Medac, Merck Serono, Mitsubishi, Pascoe, Tigercat Pharma, Sandoz Biopharmaceuticals, Sanofi-Genzyme, Schering-Plough UCB Pharma